AURA AURA BIOSCIENCES INC Operational Disruptions 8-K Filing 2023 - Positive Interim Phase 2 Data and Corporate Presentation Update Aura Biosciences, Inc. announced positive interim Phase 2 data for the treatment of early-stage choroidal melanoma and updated its corporate presentation.Get access to all SEC 8-K filings of the AURA BIOSCIENCES INC